[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (ticker: SABSW), reported a routine insider transaction dated 09/19/2025. The Form 4 shows 1,977 shares of common stock were disposed through withholding to satisfy tax obligations on vested restricted stock units (RSUs). Following the transaction, she beneficially owns 45,272 shares, which include 29,340 vested shares and 15,932 RSUs that remain subject to vesting.

The filing is a standard Section 16 disclosure reflecting tax-withholding on RSU vesting rather than an open-market sale or purchase. The form was signed by Ms. Kropotova on 09/22/2025 and does not disclose any derivative transactions or other changes in ownership form.

Positive

• Transparent disclosure of tax-withholding on RSU vesting through a timely Form 4 filing
• Clear breakdown of beneficial ownership showing vested shares and outstanding RSUs (29,340 vested; 15,932 unvested)

Negative

• Net beneficial ownership decreased by 1,977 shares due to withholding
• No additional purchases reported that might indicate increased insider accumulation

Insights

Securities Analyst

TL;DR: Routine tax-withholding on RSU vesting reduced holdings by 1,977 shares; no market sale or new grant disclosed.

The Form 4 documents a common administrative transaction where 1,977 shares were withheld to satisfy tax withholding on vested RSUs. This reduces the reporting person's beneficially owned shares to 45,272, including 15,932 unvested RSUs. From an investor-information standpoint, this is neutral: it neither signals insider selling for diversification nor a purchase that would indicate increased insider confidence. No derivative activity or other material events are reported.

Corporate Governance Expert

TL;DR: Disclosure is timely and standard; transaction reflects compensation mechanics, not a change in governance or control.

The filing properly discloses the withholding of shares to cover taxes on RSU vesting and lists the reporter's role as Chief Medical Officer. The record shows 45,272 shares beneficially owned post-transaction and clarifies that each RSU equals one share. There are no indications of new agreements, plan elections, or amendments to reporting status. This is a routine compliance disclosure with no material governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kropotova Alexandra

(Last) (First) (Middle)

777 W 41ST

SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		F		1,977(1)	D	(1)	45,272(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs").

2. Includes 29,340 shares of Common Stock and 15,932 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

3. Each RSU represents a contingent right to receive one share of Common Stock.

	Alexandra Kropotova	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did SABSW insider Alexandra Kropotova report?

The Form 4 reports that on 09/19/2025 1,977 shares were withheld to satisfy tax withholding on vested RSUs.

How many shares does Alexandra Kropotova beneficially own after the transaction?

After the withholding, she beneficially owns 45,272 shares, including 29,340 vested shares and 15,932 RSUs that remain subject to vesting.

Was the transaction a market sale or a tax-related withholding?

The filing explicitly states the shares were withheld to satisfy tax withholding requirements on RSU vesting; it is not reported as an open-market sale.

Does the Form 4 report any derivative securities or option exercises by the insider?

No. Table II for derivative securities contains no reported transactions; only non-derivative common stock withholding is disclosed.

What is Alexandra Kropotova's role at SAB Biotherapeutics as listed on the form?

She is listed as the company's Chief Medical Officer and the Form 4 is filed by one reporting person.